Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 113

Results For "NDA"

3673 News Found

Lonza reports softer performance in Q1 2024
News | May 14, 2024

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s


Coveris invests over €8 million in production capacity
Packaging | May 14, 2024

Coveris invests over €8 million in production capacity

Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany


Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
News | May 14, 2024

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024


Zydus receives final approval from USFDA for Dexamethasone Tablets
Drug Approval | May 13, 2024

Zydus receives final approval from USFDA for Dexamethasone Tablets

Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)


Briefs: Lupin and Aurobindo Pharma
News | May 13, 2024

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets


Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr
News | May 12, 2024

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr

Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024


Strides receives USFDA approval for Sevelamer Carbonate Tablets
Drug Approval | May 11, 2024

Strides receives USFDA approval for Sevelamer Carbonate Tablets

Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment


Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Drug Approval | May 10, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25


Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr
News | May 10, 2024

Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr

The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024


Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
News | May 10, 2024

Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr

The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024